Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 68788-8524

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 68788-8524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Esomeprazole Magnesium Dr Capsules Usp 40mg (2d21ed0b A089 46f4 9ebb F24f9f3af61d 00)

Label for Esomeprazole Magnesium DR Capsules, USP 40 mg, a delayed-release capsule generic for Nexium, manufactured by Graviti Pharmaceuticals. The label includes placeholders for package size, expiration date, lot number, batch number, insurance, and product number. Storage instructions and a caution against transfer are noted. Directions are provided in English and Spanish on a yellow background with space for specific dosing instructions.*

FDA Label Image

Image (B201c94c 128a 4ae1 86a1 057c4c895839 01)

Chemical structure of esomeprazole magnesium, showing the molecular arrangement including two substituted aromatic rings, a sulfoxide group, and magnesium ion complexed with three water molecules (Mg2+ 3 H2O).*

FDA Label Image

Figure 2: Maintenance Of Healing Rates By Month (study 177) (B201c94c 128a 4ae1 86a1 057c4c895839 02)

A line graph depicting percent maintained on the y-axis over months on the x-axis. It compares the maintenance rates of esomeprazole magnesium delayed-release capsules 40 mg in three groups (N=92, 98, and 91) versus a placebo group (N=94) over a six-month period.*

FDA Label Image

Figure 3: Maintenance Of Healing Rates By Month (study 178) (B201c94c 128a 4ae1 86a1 057c4c895839 03)

A line graph illustrating the percent maintained over a 6-month period for Esomeprazole Magnesium Delayed-Release Capsules at strengths of 40 mg, 20 mg, and 10 mg compared to placebo. The y-axis displays percent maintained from 0 to 100, and the x-axis represents months from 1 to 6. The 40 mg dose shows the highest maintained percent throughout the study, followed by the 20 mg and 10 mg doses, with placebo showing the lowest maintenance rates.*

FDA Label Image

Figure 4: Percent Of Patients Symptom-free Of Heartburn By Day (study 225) Figure (B201c94c 128a 4ae1 86a1 057c4c895839 04)

Line graph depicting the percent of patients symptom-free over a 28-day diary period for esomeprazole magnesium delayed-release capsules at 40 mg and 20 mg doses, compared with placebo. The x-axis represents diary days, and the y-axis shows the percent of symptom-free patients.*

FDA Label Image

Image (B201c94c 128a 4ae1 86a1 057c4c895839 05)

A line graph showing the percent of patients symptom-free over 28 diary days. It compares esomeprazole magnesium delayed-release capsules at 40 mg and 20 mg strengths with a placebo group. The y-axis represents the percent of patients symptom-free, and the x-axis shows diary days from 0 to 28.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.